Table 1.
Structures | 5-HT synthesis rate (pmol/g/min)a
|
ANOVA
|
||
---|---|---|---|---|
Controls (N=8) | Fluvoxamine (N=11) | Percent differenceb | F(1,17); p | |
Raphe nuclei | ||||
-Dorsal | 144±18 | 140±18 | −3% | 0.22 ; <0.60 |
-Median | 134±21 | 115±12 | −14% | 6.4; <0.02d |
-Magnus | 62±9 | 43±10 | −32% | 18.1 ; <0.0006c |
Cortices | ||||
-Visual | 30±5 | 41±7 | 38% | 14.3; <0.001c |
-Auditory | 26±6 | 43±9 | 65% | 21.4; <0.003c |
-Parietal | 29±7 | 39±9 | 37% | 6.8; <0.02d |
-Sensory-motor | 32±7 | 43±12 | 36% | 5.4; <0.04d |
-Frontal | 33±7 | 35±9 | 7% | 0.27; >0.60 |
Basal ganglia | ||||
-Globus pallidus | 39±10 | 48±7 | 25% | 5.36; <0.04d |
-Caudate-lateral | 38±8 | 47±10 | 23% | 4.4 ; <0.05d |
-Caudate-medial | 54±9 | 60±10 | 12% | 1.81; >0.10 |
-Nucleus accumbens | 65±9 | 68±6 | 4% | 0.76; >0.30 |
Thalamus | ||||
-Ventral | 32±5 | 42±9 | 31% | 7.99; <0.010c |
-Dorsal | 38±6 | 46±9 | 23% | 4.74; <0.050c |
Hippocampus | ||||
-Ventral | 42±5 | 59±9 | 43% | 23.0; <0.0002c |
-Dorsal | 38±8 | 54±4 | 41% | 33.0; <0.0003c |
Substantia nigra | ||||
-Reticulata | 28±4 | 34±7 | 23% | 4.7; <0.05d |
-Compacta | 30±4 | 44±9 | 56% | 16.7; <0.0008c |
Geniculate body | ||||
-Medial | 30±6 | 45±10 | 48% | 14.1; <0.002c |
-Lateral | 43±7 | 47±9 | 8% | 1.09; >0.3 |
VTA | 43±6 | 50±9 | 15% | 3.6; >0.07 |
MFB | 48±6 | 39±9 | −20% | 6.00; <0.03d |
Hypothalamus | 34±5 | 40±6 | 18% | 5.30; <0.04d |
Superior colliculus | 28±6 | 39±10 | 38% | 7.60; <0.02c |
Inferior colliculus | 24±7 | 32±7 | 29% | 6.0; <0.03d |
Superior olive | 34±17 | 34±11 | 2% | 0.08; 1.000 |
Pineal body | 705±262 | 1178±298 | Not tested |
5-HT synthesis rates are expressed as mean±SD. The number of animals is given in brackets.
Calculated as a percent (%) of the synthesis rates in the control group.
Significant difference in 5-HT synthesis rates between the fluvoxamine and control group following the Benjamini–Hochberg correction.
Identifies the brain regions with p<0.05 which lost significance following Benjamini–Hochberg correction.